Evidence map›Paper›PMID 30382424›Full record

ReviewArchives of osteoporosis2018

A brief history of FRAX.

John A Kanis, Helena Johansson, Nicholas C Harvey, Eugene V McCloskey

Abstract readHistorical ArticleReview
In one paragraph

Review in Archives of osteoporosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Systematic review of major osteoporotic fracture to hip fracture incidence rate ratios worldwide: implications for Fracture Risk Assessment Tool (FRAX)-derived estimates.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Pooled it
  4. Article
  5. Review
  6. Article
  7. Parity, age at first birth, breastfeeding, and risk of major osteoporotic fractures in middle-aged women. The HUNT study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

John A KanisCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.pontefract@shef.ac.uk.
Helena JohanssonMary McKillop Research Institute, Australian Catholic University, Melbourne, Australia.
Nicholas C HarveyMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
Eugene V McCloskeyCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.

Funding

Arthritis Research UK 17702Arthritis Research UK 21231Department of Health HTA/10/33/04Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Versus Arthritis 17702Versus Arthritis 21231
6 · The paper itself

Abstract

This paper reviews the research programme that went into the development of FRAX® and its impact in the 10 years since its release in 2008.

introductionOsteoporosis is defined on the measurement of bone mineral density though the clinical consequence is fracture. The sensitivity of bone mineral density measurements for fracture prediction is low, leading to the development of FRAX to better calculate the likelihood of fracture and target anti-osteoporosis treatments.

methodsThe method used in this paper is literature review.

resultsFRAX, developed over an 8-year period, was launched in 2008. Since the launch of FRAX, models have been made available for 64 countries and in 31 languages covering more than 80% of the world population.

conclusionFRAX provides an advance in fracture risk assessment and a reference technology platform for future improvements in performance characteristics.

Indexed as

Models, StatisticalSeverity of Illness IndexAgedBone DensityFemaleHistory, 21st CenturyHumansMiddle AgedOsteoporosisOsteoporotic FracturesRisk AssessmentRisk FactorsSensitivity and SpecificityFractureFracture probabilityFRAXOsteoporosis

Identifiers

PMID30382424
PMCPMC6290984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.